150 related articles for article (PubMed ID: 38071274)
1. Improving prognostication in patients with hepatocellular carcinoma undergoing loco-regional therapy using pre- and post-locoregional therapy scores.
Thandassery RB; Lavender CA; Perisetti A; Beheshti M
Abdom Radiol (NY); 2024 Feb; 49(2):631-641. PubMed ID: 38071274
[TBL] [Abstract][Full Text] [Related]
2. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
[TBL] [Abstract][Full Text] [Related]
3. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging.
Su TH; Liao SH; Hong CM; Liu CJ; Tseng TC; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Adhoute X; Bourlière M; Kao JH
J Gastroenterol Hepatol; 2019 Dec; 34(12):2179-2186. PubMed ID: 31062879
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study.
Vitale A; Burra P; Frigo AC; Trevisani F; Farinati F; Spolverato G; Volk M; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Cillo U;
J Hepatol; 2015 Mar; 62(3):617-24. PubMed ID: 25450706
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated With Complete Pathologic Necrosis of Hepatocellular Carcinoma on Explant Evaluation After Locoregional Therapy: A National Analysis Using the UNOS Database.
Sarwar A; Bonder A; Hassan L; Malik MS; Novack V; Curry M; Ahmed M
AJR Am J Roentgenol; 2023 May; 220(5):727-735. PubMed ID: 36475810
[No Abstract] [Full Text] [Related]
6. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
[TBL] [Abstract][Full Text] [Related]
7. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study.
Shin J; Yu JH; Jin YJ; Suh YJ; Kim DH; Byun S; Lee JW
Medicine (Baltimore); 2019 Jul; 98(30):e16150. PubMed ID: 31348228
[TBL] [Abstract][Full Text] [Related]
8. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
10. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
[TBL] [Abstract][Full Text] [Related]
11. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
12. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
[TBL] [Abstract][Full Text] [Related]
13. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
[TBL] [Abstract][Full Text] [Related]
14. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
15. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
Salem R; Gabr A; Riaz A; Mora R; Ali R; Abecassis M; Hickey R; Kulik L; Ganger D; Flamm S; Atassi R; Atassi B; Sato K; Benson AB; Mulcahy MF; Abouchaleh N; Asadi AA; Desai K; Thornburg B; Vouche M; Habib A; Caicedo J; Miller FH; Yaghmai V; Kallini JR; Mouli S; Lewandowski RJ
Hepatology; 2018 Oct; 68(4):1429-1440. PubMed ID: 29194711
[TBL] [Abstract][Full Text] [Related]
16. MELD-Na > 16 is associated with high peri-procedural and short-term mortality in patients with ruptured hepatocellular carcinoma treated with emergent transarterial embolization.
Jundt MC; Owen RL; Thompson SM; Fleming CJ; Stockland AH; Andrews JC
Abdom Radiol (NY); 2022 Jan; 47(1):416-422. PubMed ID: 34633495
[TBL] [Abstract][Full Text] [Related]
17. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma.
Vogeler M; Mohr I; Pfeiffenberger J; Sprengel SD; Klauss M; Teufel A; Chang DH; Springfeld C; Longerich T; Merle U; Mehrabi A; Weiss KH; Mieth M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1033-1050. PubMed ID: 32107625
[TBL] [Abstract][Full Text] [Related]
18. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
[TBL] [Abstract][Full Text] [Related]
19. The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.
Op den Winkel M; Nagel D; Op den Winkel P; Paprottka PM; Schmidt L; Bourhis H; Trojan J; Goeller M; Reiter FP; Stecher SS; De Toni EN; Gerbes AL; Kolligs FT
Digestion; 2019; 100(1):15-26. PubMed ID: 30282074
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T; Nezami N; Laage Gaupp F; Savic LJ; Taddei T; Jaffe A; Strazzabosco M; Lin M; Duran R; Georgiades C; Hong K; Chapiro J
Radiology; 2022 Jul; 304(1):228-237. PubMed ID: 35412368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
